Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This multisite prospective study seeks to determine if HLA-identical sibling donor
transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle
transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant
while achieving a high cure rate for children with sickle cell disease (SCD).
Phase:
Phase 2
Details
Lead Sponsor:
Allistair Abraham, MD
Collaborators:
Alberta Children's Hospital Ann & Robert H Lurie Children's Hospital of Chicago Levine Children's Hospital The Hospital for Sick Children